Literature DB >> 12552018

Identification of a TAP-independent, immunoproteasome-dependent CD8+ T-cell epitope in Epstein-Barr virus latent membrane protein 2.

Georg Lautscham1, Tracey Haigh, Sabine Mayrhofer, Graham Taylor, Debbie Croom-Carter, Alison Leese, Stephan Gadola, Vincenzo Cerundolo, Alan Rickinson, Neil Blake.   

Abstract

We have identified an HLA-A2-restricted CD8(+) T-cell epitope, FLYALALLL, in the Epstein-Barr virus (EBV) latent membrane protein 2 (LMP2), an important target antigen in the context of EBV-associated malignancies. This epitope is TAP independent, like other hydrophobic LMP2-derived epitopes, but uniquely is dependent upon the immunoproteasome for its generation.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12552018      PMCID： PMC141109          DOI： 10.1128/jvi.77.4.2757-2761.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  29 in total

Review 1.  The 26S proteasome: a molecular machine designed for controlled proteolysis.

Authors:  D Voges; P Zwickl; W Baumeister
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

2.  Epstein-Barr virus-specific cytotoxic T lymphocyte responses in the blood and tumor site of Hodgkin's disease patients: implications for a T-cell-based therapy.

Authors:  A L Chapman; A B Rickinson; W A Thomas; R F Jarrett; J Crocker; S P Lee
Journal:  Cancer Res       Date:  2001-08-15       Impact factor: 12.701

Review 3.  The role of the proteasome activator PA28 in MHC class I antigen processing.

Authors:  Alice Sijts; Yuancheng Sun; Katarina Janek; Sylvie Kral; Annettte Paschen; Dirk Schadendorf; Peter-M Kloetzel
Journal:  Mol Immunol       Date:  2002-10       Impact factor: 4.407

4.  MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells.

Authors:  A J Sijts; S Standera; R E Toes; T Ruppert; N J Beekman; P A van Veelen; F A Ossendorp; C J Melief; P M Kloetzel
Journal:  J Immunol       Date:  2000-05-01       Impact factor: 5.422

5.  Generation of an immunodominant CTL epitope is affected by proteasome subunit composition and stability of the antigenic protein.

Authors:  U Gileadi; H T Moins-Teisserenc; I Correa; B L Booth; P R Dunbar; A K Sewell; J Trowsdale; R E Phillips; V Cerundolo
Journal:  J Immunol       Date:  1999-12-01       Impact factor: 5.422

6.  Correlation of sequence hydrophobicities measures similarity in three-dimensional protein structure.

Authors:  R M Sweet; D Eisenberg
Journal:  J Mol Biol       Date:  1983-12-25       Impact factor: 5.469

7.  Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity.

Authors:  L Meng; R Mohan; B H Kwok; M Elofsson; N Sin; C M Crews
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

8.  Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.

Authors:  C M Rooney; C A Smith; C Y Ng; S K Loftin; J W Sixbey; Y Gan; D K Srivastava; L C Bowman; R A Krance; M K Brenner; H E Heslop
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113

9.  Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.

Authors:  A J Sijts; T Ruppert; B Rehermann; M Schmidt; U Koszinowski; P M Kloetzel
Journal:  J Exp Med       Date:  2000-02-07       Impact factor: 14.307

10.  Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.

Authors:  G Lautscham; S Mayrhofer; G Taylor; T Haigh; A Leese; A Rickinson; N Blake
Journal:  J Exp Med       Date:  2001-10-15       Impact factor: 14.307
View more
  16 in total

1.  Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.

Authors:  Yoshinori Ito; Eisei Kondo; Ayako Demachi-Okamura; Yoshiki Akatsuka; Kunio Tsujimura; Mitsune Tanimoto; Yasuo Morishima; Toshitada Takahashi; Kiyotaka Kuzushima
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  A novel latent membrane 2 transcript expressed in Epstein-Barr virus-positive NK- and T-cell lymphoproliferative disease encodes a target for cellular immunotherapy.

Authors:  Christopher P Fox; Tracey A Haigh; Graham S Taylor; Heather M Long; Steven P Lee; Claire Shannon-Lowe; Simon O'Connor; Catherine M Bollard; Javeed Iqbal; Wing C Chan; Alan B Rickinson; Andrew I Bell; Martin Rowe
Journal:  Blood       Date:  2010-07-29       Impact factor: 22.113

3.  Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agent.

Authors:  Xiaoyun Lin; Shao Chen; Xiangyang Xue; Lijun Lu; Shanli Zhu; Wenshu Li; Xiangmin Chen; Xiaozhi Zhong; Pengfei Jiang; Torsoo Sophia Sename; Yi Zheng; Lifang Zhang
Journal:  Cell Mol Immunol       Date:  2015-04-13       Impact factor: 11.530

4.  RNAs in Epstein-Barr virions control early steps of infection.

Authors:  Simon Jochum; Romana Ruiss; Andreas Moosmann; Wolfgang Hammerschmidt; Reinhard Zeidler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-27       Impact factor: 11.205

5.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

Review 6.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

7.  Immunodominant West Nile Virus T Cell Epitopes Are Fewer in Number and Fashionably Late.

Authors:  Saghar Kaabinejadian; Curtis P McMurtrey; Sojung Kim; Rinki Jain; Wilfried Bardet; Fredda B Schafer; Jason L Davenport; Aaron D Martin; Michael S Diamond; Jon A Weidanz; Ted H Hansen; William H Hildebrand
Journal:  J Immunol       Date:  2016-04-20       Impact factor: 5.422

8.  Novel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccine.

Authors:  Viviana P Lutzky; Monika Corban; Lea Heslop; Leanne E Morrison; Pauline Crooks; David F Hall; William B Coman; Scott A Thomson; Denis J Moss
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

9.  Generating functional CD8+ T cell memory response under transient CD4+ T cell deficiency: implications for vaccination of immunocompromised individuals.

Authors:  Corey Smith; Michelle Martinez; Leanne Cooper; Michael Rist; Jie Zhong; Rajiv Khanna
Journal:  Eur J Immunol       Date:  2008-07       Impact factor: 5.532

10.  Potential selection of LMP1 variants in nasopharyngeal carcinoma.

Authors:  Rachel H Edwards; Diane Sitki-Green; Dominic T Moore; Nancy Raab-Traub
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.